UNMC_Acronym_Vert_sm_4c
University of Nebraska Medical Center

Bavarian Nordic reveals positive mpox vaccine trial data in children

Clinical Trials The trial involved 227 children and 224 adults, with the significant immune responses in children aged two to five years. Bavarian Nordic has announced encouraging topline results from a clinical trial assessing its MVA-BN mpox/smallpox vaccine in children aged between two and 11 years.

The trial involved 460 participants across two cohorts, examining the immunogenicity and safety of two standard vaccine doses in both paediatric and adult populations aged 18–50 years.

It was jointly funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and took place at various locations in the Democratic Republic of Congo and Uganda.

twitter facebook bluesky email print

Leave a comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.